SearchSkip to Search Results
Characterization of a novel model of intestinal lipoprotein overproduction and the impact of N-3 PUFA supplementationDownload
Overproduction of intestinal chylomicrons (CM) has been proposed to contribute to fasting and post-prandial (PP) dyslipidemia and may accelerate the development of cardiovascular disease (CVD) during obesity, insulin resistance (IR) and diabetes. However, the impact of morphological changes in...
The Role of Intestinal Derived Remnant Lipoproteins in the Progression of Atherosclerosis in Animal Models of Type 1 and Type 2 Diabetes.Download
Introduction: Subjects with insulin resistance (IR) and diabetes are at increased risk of cardiovascular disease (CVD) than those without diabetes, however the mechanistic basis remains elusive. Despite LDL-cholesterol lowering by statin therapy, two-thirds of all CVD events remain, constituting...
The hypolipidemic benefits of trans-11 vaccenic acid in a rat model of dyslipidemia and metabolic syndromeDownload
Trans-11 vaccenic acid (VA) is the predominant trans fatty acid in dairy fat and is the major precursor to endogenous synthesis of cis9,trans11-conjugated linoleic acid (CLA) in humans and animals. Epidemiological studies have shown the positive association between trans fat intake and incidence...
The role of ezetimibe and simvastatin in modulating intestinal cholesterol transport, chylomicron profile and chylomicron-remnant uptake by the arterial wall in a rodent model of the metabolic syndromeDownload
Intestinally derived chylomicron remnants (CM-r) may contribute to atherogenic dyslipidemia during the Metabolic Syndrome (Mets). However, the combined effects of ezetimibe (EZ) and simvastatin (SV) on post-prandial (PP) dyslipidemia during MetS remains unclear, nor is it known whether the...